Sonnet biotherapeutics releases virtual investor ‘”what this means” segment

Drs. pankaj mohan, ceo of sonnet, and john cini, cso of sonnet, discuss the company's recent issuance of a u.s. patent covering a variant of il-18 incorporated into two novel immunotherapeutic drug candidates, son-1400 and son-1411
SONN Ratings Summary
SONN Quant Ranking